# US 2026/0091041 A1 · Methods of Treating Heavy Menstrual Bleeding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091041 A1
- Document ID: US20260091041A1
- Status: Published application
- Kind: A1
- Application number: 19/301,199
- Filed: 2025-08-15
- Published: 2026-04-02
- Earliest claimed: 2018-04-19
- Applicants: AbbVie Inc.
- Inventors: Kristof Chwalisz; Jane Castelli-Haley; Oscar Antunez Flores; Keith Gordon; Rita Jain; Juki Wing-Keung Ng; Janine D. North; Charlotte D. Owens; Hannah Palac; Paul M. Peloso; Michael C. Snabes; Ahmed M. Soliman; James W. Thomas; Mohamad Shebley
- Web page: https://patentgrep.com/patent/US20260091041A1

## CPC

- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

## Claims

### Claim 1

A method of treating endometriosis associated pain wherein the method further reduces fatigue in a patient with moderate to severe endometriosis, the method comprising administering to 4-((R)-2-15-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein Compound A or its pharmaceutically acceptable salt is administered in combination with estrogens and progestogens wherein the estrogen is selected from the group consisting of estradiol, ethinyl estradiol, and conjugated estrogens, and the progestogen is selected from the group consisting of progesterone, norethindrone acetate, norgestimate, drospirenone, and medroxyprogesterone.

### Claim 3 (depends on 2)

The method of claim 2, wherein the estrogen is estradiol and the progestogen is norethindrone acetate.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 3)

The method of claim 3, wherein the estradiol is administered in an amount of about 1.0 mg and the norethindrone acetate is administered in an amount of about 0.5 mg per day.

### Claim 7 (depends on 6)

The method of claim 6, wherein the estradiol and norethindrone acetate are administered once per day.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein Compound A is dosed 150 mg once-a-day, 200 mg twice-a-day, or 300 mg twice-a-day.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof is administered in an amount of about 400 mg per day.

### Claim 13 (depends on 12)

The method of claim 12, wherein 4-((R)-245-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof is administered twice per day.

### Claim 14 (depends on 2)

The method of claim 2, wherein 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyriinidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof is administered in an amount of about 600 mg per day.

### Claim 15 (depends on 14)

The method of claim 14, wherein 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof is administered twice per day.

### Claim 16 (depends on 2)

The method of claim 2, wherein 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, estrogens, and progestogens are administered daily for at least 28 days.

### Claim 17 (depends on 16)

The method of claim 16, wherein 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, estrogens, and progestogens are administered daily for at least 56 days.

### Claim 18 (depends on 17)

The method of claim 17, wherein 4-((R)-245-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, estrogens, and progestogens are administered daily for at least 84 days.

### Claim 19 (depends on 18)

The method of claim 18, wherein 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, estrogens, and progestogens are administered daily for at least 168 days.

### Claim 20 (depends on 19)

The method of claim 19, wherein 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, estrogens, and progestogens are administered daily for about 168 days to about 1 year.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 1)

The method of claim 1, further wherein said patient experiences bone mineral density loss, wherein the bone mineral density loss is substantially reversed upon discontinuation of Compound A, or pharmaceutically acceptable salt thereof.

### Claim 29

(canceled)

### Claim 30

A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient suffering from endometriosis and having hepatic impairment, the method comprising:
identifying the patient as having hepatic impairment classified as Child-Pugh A or Child-Pugh B,
orally administering a sodium salt of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (“elagolix sodium”) to the patient according to a dosing schedule for patients having hepatic impairment, wherein the dosing schedule for patients having hepatic impairment comprises:
administration of a tablet comprising 155.2 mg of elagolix sodium once daily for up to 24 months or administration of a tablet comprising 207.0 mg of elagolix sodium twice daily for up to 6 months in patients having hepatic impairment classified as Child-Pugh A, and
administration of a tablet comprising 155.2 mg of elagolix sodium once daily for up to 6 months in patients having hepatic impairment classified as Child-Pugh B;
wherein said method manages the moderate to severe pain associated with endometriosis in the patient.

### Claim 31

A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient suffering from endometriosis and having hepatic impairment, the method comprising:
orally administering a sodium salt of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (“elagolix sodium”) to the patient according to a dosing schedule for patients having hepatic impairment, wherein the dosing schedule for patients having hepatic impairment comprises:
administration of a tablet comprising 155.2 mg of elagolix sodium once daily for up to 24 months or administration of a tablet comprising 207.0 mg of elagolix sodium twice daily for up to 6 months in patients having hepatic impairment classified as Child-Pugh A, and
administration of a tablet comprising 155.2 mg of elagolix sodium once daily for up to 6 months in patients having hepatic impairment classified as Child-Pugh B;
wherein said method manages the moderate to severe pain associated with endometriosis in the patient.
